Background. Probiotic oral intake, via modulation of the microbiota-gut-brain axis, can impact brain activity, mood, and behavior; therefore, it may be beneficial against psychological distress and anxiety disorders. Inflammatory cytokines can influence the onset and progression of several neurodegenerative mood disorders, and the IL-1 beta rs16944 SNP is related to high cytokine levels and potentially affects mood disorders. The aim of this study was to examine the combined effect of IL-1 beta polymorphism and probiotic administration in mood disorder phenotypes in the Italian population. Methods. 150 subjects were randomized into two different groups, probiotic oral suspension group (POSG) and placebo control group (PCG), and received the relative treatment for 12 weeks. Psychological profile assessment by Hamilton Anxiety Rating Scale (HAM-A), Body Uneasiness Test (BUT), and Symptom Checklist 90-Revised (SCL90R) was administered to all volunteers. Genotyping was performed on DNA extracted from salivary samples. Results. After 12 weeks of intervention, a significant reduction of HAM-A total score was detected in the POSG (p<0.01), compared to the PCG. Furthermore, IL-1 beta carriers have moderate risk to develop anxiety (OR=5.90), and in POSG IL-1 beta carriers, we observed a reduction of HAM-A score (p=0.02). Conclusions. Consumption of probiotics mitigates anxiety symptoms, especially in healthy adults with the minor A allele of rs16944 as a risk factor. Our results encourage the use of probiotics in anxiety disorders and suggest genetic association studies for psychobiotic-personalized therapy.

Gualtieri, P., Marchetti, M., Cioccoloni, G., De Lorenzo, A., Romano, L., Cammarano, A., et al. (2020). Psychobiotics regulate the anxiety symptoms in carriers of allele A of IL-1 β Gene: A randomized, placebo-controlled clinical trial. MEDIATORS OF INFLAMMATION, 2020, 1-11 [10.1155/2020/2346126].

Psychobiotics regulate the anxiety symptoms in carriers of allele A of IL-1 β Gene: A randomized, placebo-controlled clinical trial

Gualtieri P.;Marchetti M.;Cioccoloni G.;De Lorenzo A.;Cammarano A.;Condo R.;Di Renzo L.
2020

Abstract

Background. Probiotic oral intake, via modulation of the microbiota-gut-brain axis, can impact brain activity, mood, and behavior; therefore, it may be beneficial against psychological distress and anxiety disorders. Inflammatory cytokines can influence the onset and progression of several neurodegenerative mood disorders, and the IL-1 beta rs16944 SNP is related to high cytokine levels and potentially affects mood disorders. The aim of this study was to examine the combined effect of IL-1 beta polymorphism and probiotic administration in mood disorder phenotypes in the Italian population. Methods. 150 subjects were randomized into two different groups, probiotic oral suspension group (POSG) and placebo control group (PCG), and received the relative treatment for 12 weeks. Psychological profile assessment by Hamilton Anxiety Rating Scale (HAM-A), Body Uneasiness Test (BUT), and Symptom Checklist 90-Revised (SCL90R) was administered to all volunteers. Genotyping was performed on DNA extracted from salivary samples. Results. After 12 weeks of intervention, a significant reduction of HAM-A total score was detected in the POSG (p<0.01), compared to the PCG. Furthermore, IL-1 beta carriers have moderate risk to develop anxiety (OR=5.90), and in POSG IL-1 beta carriers, we observed a reduction of HAM-A score (p=0.02). Conclusions. Consumption of probiotics mitigates anxiety symptoms, especially in healthy adults with the minor A allele of rs16944 as a risk factor. Our results encourage the use of probiotics in anxiety disorders and suggest genetic association studies for psychobiotic-personalized therapy.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/49
English
Gualtieri, P., Marchetti, M., Cioccoloni, G., De Lorenzo, A., Romano, L., Cammarano, A., et al. (2020). Psychobiotics regulate the anxiety symptoms in carriers of allele A of IL-1 β Gene: A randomized, placebo-controlled clinical trial. MEDIATORS OF INFLAMMATION, 2020, 1-11 [10.1155/2020/2346126].
Gualtieri, P; Marchetti, M; Cioccoloni, G; De Lorenzo, A; Romano, L; Cammarano, A; Colica, C; Condo, R; Di Renzo, L
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/278300
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 10
social impact